LZD-induced dyserythropoiesis: Chloramphenicol toxicity revisited

University of Vic, Vic, Catalonia, Spain
Internal Medicine Journal (Impact Factor: 1.7). 11/2005; 35(10):626-8. DOI: 10.1111/j.1445-5994.2005.00912.x
Source: PubMed

ABSTRACT We report here two cases of dyserythropoietic anaemia associated with long-term linezolid use that share striking similarities to chloramphenicol-associated myelotoxicity.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Mycobacterium abscessus is the most pathogenic and chemotherapy-resistant rapid-growing mycobacterium. It is commonly associated with contaminated traumatic skin wounds and with post-surgical soft tissue infections. It is also one of the mycobacteria that are most often isolated from cystic fibrosis patients. It is essential to differentiate this species from the formerly indistinct "M. chelonae-complex", as chemotherapy is especially difficult in M. abscessussenso strictu. Clarithromycin or azithromycin are the only regular oral antimycobacterial agents with an effect on M. abscessus, and should preferably be supplemented with other drugs since long-term monotherapy may cause resistance. Amikacin is a major parenteral drug against M. abscessus that should also be given in combination with another drug. The recently introduced drug tigecycline may prove to be an important addition to chemotherapy, but has yet to be fully clinically evaluated as an antimycobacterial agent. Surgery can be curative, or at least helpful, in the healing of M. abscessus infection, and if conducted, it should include the removal of all foreign or necrotic material. There is increasing awareness of M. abscessus as an emerging pathogen.
    Apmis 06/2006; 114(5):319-28. DOI:10.1111/j.1600-0463.2006.apm_390.x · 1.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Complications of long-term linezolid administration include anemia and thrombocytopenia. A recent report has suggested that pyridoxine may prevent myelosuppression. Pyridoxine was administered to 24 patients with bone infections who were being treated with linezolid. Thrombocytopenia occurred in 11 patients (45.8%), and anemia occurred in 6 (25%). We concluded that treatment wtih pyridoxine is unlikely to benefit patients who have been receiving linezolid for >2 weeks.
    Clinical Infectious Diseases 11/2006; 43(9):e89-91. DOI:10.1086/508280 · 9.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Linezolid is a recent oral antibiotic used in drug-resistant Gram-positive cocci infection. We herein report on the first two cases of linezolid-related pancytopenia in organ-transplant patients. Both patients had methicillineresistant Staphylococcus aureus infections. Pancytopenia, i.e. aregenerative anemia, neutropenia and thrombopenia, developed 3 weeks and 5 weeks after initiating linezolid therapy at a conventional dosage (600 mg bid). There were no other confounding causes of pancytopenia, which resolved promptly after withdrawing linezolid. Because of the potential hazards of pancytopenia in immunosuppressed organ-transplant patients, we advocate the cautious use of linezolid for transplant patients.
    Infection 07/2007; 35(4):275-7. DOI:10.1007/s15010-007-6197-6 · 2.86 Impact Factor
Show more